6 completed, 4 recruiting, 2 active not recruiting, 1 suspended. 16 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 6, Recruiting 4, Active not recruiting 2, Suspended 1, Terminated 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 6 | Recruiting 3, Completed 2, Terminated 1 |
Follow Breast Adenocarcinoma: new trials by email Literature Review of Breast Adenocarcinoma trials Research Report on Breast Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer SBRT, Immuno-chemotherapy - Breast Adenocarcinoma | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 74 | 2024-12-26 | 2025-02-11 |
| Assessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy SBRT, Chemotherapy - Breast Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 96 | 2024-12-25 | 2025-12-30 |
| High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer Biospecimen Collection, BRC-001, Placebo Administration - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 2 | Suspended | City of Hope Medical Center | 36 | 2024-08-26 | 2026-07-14 |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) Rina-S, Carboplatin, Bevacizumab - High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer | Phase 1 / Phase 2 | Recruiting | Genmab | 952 | 2022-12-07 | 2026-11-04 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Placebo Administration - Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7 | Phase 2 | Unknown | Academic and Community Cancer Research United | 480 | 2020-02-20 | 2023-12-18 |
| Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib Neratinib, Trastuzumab, Loperamide - HER2-positive Breast Cancer, Breast Adenocarcinoma | Phase 2 | Completed | University of California, San Francisco | 11 | 2018-10-09 | 2025-06-26 |
| Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy Carbon Dioxide Fractional Laser, Questionnaire Administration - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 2 | Withdrawn | Mayo Clinic | 2018-09-10 | 2023-01-06 | |
| Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer Binimetinib, Laboratory Biomarker Analysis, Pembrolizumab - Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 23 | 2017-09-27 | 2025-06-27 |
| Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer H3B-6545 - Breast Neoplasms, Breast Cancer | Phase 1 / Phase 2 | Completed | Eisai Inc. | 151 | 2017-08-23 | 2025-02-25 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Doxorubicin, Cyclophosphamide, Paclitaxel - Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer | Phase 2 | Active not recruiting | Virginia Commonwealth University | 46 | 2017-01-24 | 2026-07-01 |
| Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer Atezolizumab, Nab-paclitaxel - Breast Adenocarcinoma, Invasive Breast Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 37 | 2016-02-04 | 2026-02-17 |
| Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer Laboratory Biomarker Analysis, Talazoparib - Breast Adenocarcinoma, Deleterious BRCA1 Gene Mutation | Phase 2 | Completed | M.D. Anderson Cancer Center | 36 | 2015-04-16 | 2022-07-06 |
| Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer pertuzumab, trastuzumab, paclitaxel albumin-stabilized nanoparticle formulation - HER2-positive Breast Cancer, Recurrent Breast Cancer | Phase 2 | Completed | City of Hope Medical Center | 63 | 2013-07-25 | 2026-11-03 |
| PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Breast Adenocarcinoma, Estrogen Receptor Positive | Phase 1 / Phase 2 | Terminated | Prescient Therapeutics, Ltd. | 34 | 2012-01-01 | 2020-09-24 |
| Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer Accelerated Partial Breast Irradiation, Proton Beam Radiation Therapy, Quality-of-Life Assessment - Breast Adenocarcinoma, Ductal Breast Carcinoma In Situ | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 200 | 2010-11-15 | 2026-05-01 |
Breast Neoplasms (10) · Triple Negative Breast Neoplasms (5) · Breast Carcinoma In Situ (3) · Carcinoma, Intraductal, Noninfiltrating (2) · Carcinoma, Non-Small-Cell Lung (2) · Endometrial Neoplasms (2) · Uterine Cervical Neoplasms (2) · Carcinoma, Hepatocellular (1) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Carcinosarcoma (1) · Dyspareunia (1) · Fallopian Tube Neoplasms (1)
Breast Diseases (14) · Neoplasms (14) · Neoplasms by Site (14) · Skin Diseases (14) · Skin and Connective Tissue Diseases (14) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Breast Neoplasms (4) · Carcinoma (4) · Adenocarcinoma (3) · Carcinoma in Situ (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genital Diseases (3) · Genital Diseases, Female (3)
pembrolizumab (4) · Albumin-Bound Paclitaxel (3) · Cyclophosphamide (3) · Taxes (3) · Trastuzumab (3) · 130-nm albumin-bound paclitaxel (2) · 2C4 antibody (2) · Carboplatin (2) · Colony-Stimulating Factors (2) · Doxorubicin (2) · Paclitaxel (2) · Specimen Handling (2) · pertuzumab (2) · sargramostim (2) · Ado-Trastuzumab Emtansine (1)
M.D. Anderson Cancer Center (3) · Mayo Clinic (3) · City of Hope Medical Center (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Academic and Community Cancer Research United (1) · Eisai Inc. (1) · Genmab (1) · Prescient Therapeutics, Ltd. (1) · University of California, San Francisco (1) · Virginia Commonwealth University (1)
United States (13) · China (3) · France (1) · Japan (1) · South Korea (1) · United Kingdom (1)
Saranya Chumsri (2) · Clinton Yam (1) · Harry D. Bear, M.D., Ph.D. (1) · Jennifer K Litton (1) · Jo Chien, MD (1) · Joanne Mortimer, MD (1) · Joseph Sparano (1) · Lisa D Yee (1) · Melissa Mitchell, MD (1) · Saranya Chumsri, M.D. (1) · Yanyan Lou, MD, PhD (1)
PMID 31461380, PMID 35642432, PMID 35736816, PMID 37061619, PMID 40830892
2018 (1), P30CA013330 (1), P30CA015083 (1), P30CA016059 (1), P30CA033572 (1), R01CA098473 (1), R01CA166020 (1)